Thursday, March 29, 2012
A Harvard Medical School team has
identified a T cell-based immune response in the skin that does a better job of
protecting mice from some viral infections than circulating T cells.1
TremRx Inc. is using associated
proprietary technology as the basis of a vaccine platform against infectious
diseases and cancer.
Back to the
Baas, T. SciBX 5(13);
doi:10.1038/scibx.2012.322 Published online March 29, 2012
1. Jiang, X. et al. Nature; published
online Feb. 29, 2012; doi:10.1038/nature10851 Contact: Thomas S. Kupper, Brigham and Women's Hospital,
Boston, Mass. e-mail: email@example.com
2. Liu, L. et al. Nat. Med. 16, 224-227 (2010)
3. Clark, R.A. et al. Sci. Transl.
Med. 4, 117ra7 (2012)
AND INSTITUTIONS MENTIONED
Brigham and Women's Hospital, Boston, Mass.
Dana-Farber Cancer Institute, Boston, Mass.
Harvard Medical School, Boston, Mass.
Imperial College London, London, U.K.
Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J.
(Euronext:SAN; NYSE:SNY), Paris, France
TremRx Inc., Boston, Mass.
Medical Center Groningen, Groningen, the Netherlands